For example, in lung and breast cancer, lncRNA NKILA can upregulate the sensitivity of tumor-specific cytotoxic T lymphocytes and type 1 helper T cells to activation-induced cell death by inhibiting NF-κB activity, thereby facilitating immune escape [49]. Here, NKILA is linked to neoplasm.